Equipalazone Injection 50ml-Hyperdrug

Equipalazone Injection is indicated in the treatment of musculoskeletal disorders in horses and ponies where the anti-inflammatory and analgesic properties of Phenylbutazone can offer relief against inflammation, pain and lameness. A sterile aqueous solution for injection, containing Phenylbutazone 200 mg/ml. Preservative: Benzyl Alcohol 1.5 % v/v

Presentation A sterile aqueous solution for parenteral administration containing Phenylbutazone PhEur 200 mg/ml. Preservative: Benzyl Alcohol PhEur 1.5% v/v. Uses For the treatment of musculoskeletal disorders in horses and ponies where the anti-inflammatory and analgesic properties of phenylbutazone can offer relief against inflammation, pain and lameness.

Dosage and administration Horses 450 kg (1,000 lb) body weight Maximum 10 ml (4.4 mg phenylbutazone/kg). Ponies 225 kg (500 lb) body weight Maximum 5 ml (4.4 mg phenylbutazone/kg). Equipalazone Injection should be administered by slow intravenous injection as a single dose, which may be followed if necessary by oral phenylbutazone therapy commencing 24 hours after the injection. In acute cases and in hospitalised patients, Equipalazone Injection may be administered once daily for not more than five consecutive days.

Contra-indications, warnings, etc Do not use in horses intended for human consumption. The therapeutic index of phenylbutazone is low. Do not exceed the stated dose or the duration of treatment. Use is contra-indicated in animals suffering from cardiac, hepatic or renal disease, where there is the possibility of gastro-intestinal ulceration or bleeding, or where there is evidence of a blood dyscrasia or hypersensitivity to the product. Do not administer other NSAIDs concurrently or within 24 hours of each other. There is a risk of irritancy if the injection is accidentally inoculated under the skin during intravenous injection. The product should be handled with care at all times to reduce the risk of accidental ingestion, skin contact or self-injection. If accidental skin or eye contact occurs, the site should be washed immediately with water. If the product is ingested, seek medical advice and show the product packaging. Advice to doctors: gastric lavage (emesis in children) should be performed urgently. Charcoal haemoperfusion has also been shown to be beneficial. Treatment should then be administered symptomatically. If the product is self-injected, seek medical advice and show the product packaging. Some NSAIDs may be highly bound to plasma proteins and compete with other highly bound drugs to produce an increase in non-bound pharmacologically active concentrations, which can lead to toxic effects. Use in animals less than 6 weeks of age, or in aged animals may involve additional risk. If such use cannot be avoided, animals may require a reduced dosage and careful clinical management. Avoid use in any dehydrated, hypovolaemic or hypotensive animals as there is a risk of increased renal toxicity. Concurrent administration of potentially nephrotoxic drugs should be avoided. It is preferable that NSAIDs which inhibit prostaglandin synthesis are not administered to animals undergoing general anaesthesia until fully recovered. Use during pregnancy should be avoided whenever possible, particularly during the first trimester. Pharmaceutical precautions Store between +2 and +8°C. Protect from light. Following withdrawal of the first dose use the product within 28 days. Discard unused material. Dispose of any unused product or containers in accordance with guidance from your local waste regulation authority, e.g. the local regional office of the Environment Agency or SEPA. General precautions Keep out of the reach of children. For animal treatment only. NSAIDs can cause inhibition of phagocytosis and hence in the treatment of inflammatory conditions associated with bacterial infections, appropriate concurrent antimicrobial therapy should be instigated.

Legal category POM-V (previously POM). Packaging Quantities Multidose vials of 50 ml Further information The clinical effect of phenylbutazone can be evident for at least three days following cessation of administration. This should be borne in mind when examining horses for soundness. Some racing authorities (including the British Jockey Club) regard phenylbutazone as a ‘prohibited substance’ within their racing rules. The Royal College of Veterinary Surgeons has given guidance to the veterinary profession regarding the elimination times of various anti-inflammatory drugs and they state “if a veterinarian recommends the discontinuance of any such drug not less than eight days before racing, he should be able to feel that he has catered for all but the most exceptional circumstances”. Marketing authorisation number Vm 01732/4082.